Argos fully enrolls its trial to test a cancer therapy

Argos is developing a therapy to treat metastatic renal cell carcinoma (mRCC) and hit the enrollment goal of 450 randomized patients. This is a Phase 3 trial, meaning it is one of the last major steps a drug developer takes before submitting an application with the U.S. Food and Drug Administration.07/16/2015
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news

Related Links:

Conclusions: Early favorable signs of FDG-PET parameters may vary among diseases with immune checkpoint inhibitors. Mean FDG uptake was elevated in several immune-related organs at the early restaging scan. Among them, elevated FDG accumulation in thyroid might be a candidate sign of monitoring effectiveness of immunotherapy observed earlier than immune-related lymphadenopathy. Relationship between % change () of PET parameters and patients outcome% chage (Î") of PET parametersMalignant melanoma(Odds, 95%CI, p)Malignant lymphoma (Odds, 95%CI, p)Renal cell carcinoma (Odds, 95%CI, p)Î&quo...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Other Solid Tumors Source Type: research
The Functional Assessment of Cancer Therapy –Kidney Symptom Index Disease-Related Symptoms (FKSI-DRS) is important to gauge clinical benefit in metastatic renal cell carcinoma (mRCC).
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research
Authors: Buoninfante OA, Pilzecker B, Aslam MA, Zavrakidis I, van der Wiel R, van de Ven M, van den Berk PCM, Jacobs H Abstract DNA damage tolerance (DDT) enables replication to continue in the presence of a damaged template and constitutes a key step in DNA interstrand crosslink repair. In this way DDT minimizes replication stress inflicted by a wide range of endogenous and exogenous agents, and provides a critical first line defense against alkylating and platinating chemotherapeutics. Effective DDT strongly depends on damage-induced, site-specific PCNA-ubiquitination at Lysine (K) 164 by the E2/E3 complex (RAD6/...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
In conclusion, our data show that Notch signaling affects the hypoxic response via regulation of HIF2a, which may be important for future cancer therapies.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Abstract As a treatment for solid tumors, dendritic cell (DC)-based immunotherapy has not been as effective as expected. Here, we review the reasons underlying the limitations of DC-based immunotherapy for solid tumors and ask what can be done to improve immune cell-based cancer therapies. Several reports show that, rather than a lack of immune induction, the limited efficacy of DC-based immunotherapy in cases of renal cell carcinoma (RCC) likely results from inhibition of immune responses by tumor-secreted TGF-β and an increase in the number of regulatory T (Treg) cells in and around the solid tumor. Indeed,...
Source: Translational Oncology - Category: Cancer & Oncology Authors: Tags: Transl Oncol Source Type: research
SummaryImmunotherapies comprise of a  class of cancer therapies that are increasingly used for treatment of several cancer entities. Active immunotherapies encompassing immune checkpoint inhibitors are the most widespread class of immunotherapies, with indications for melanoma, non-small lung cancer, renal cell carcinoma, urothelial c arcinoma, head and neck squamous cell carcinoma, and Hodgkin’s lymphoma. Immune checkpoint inhibitors have demonstrated unique response patterns that are not adequately captured by traditional response criteria such das the Response Evaluation Criteria in Solid Tumors (RECIST) and ...
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research
Summary Nivolumab belongs to the standard therapy in the second‐line setting of metastatic renal cell carcinoma (mRCC). Although deep and long‐lasting responses are seen in some patients, the majority of patients will further progress. PD‐L1 as predictive biomarker is still under critical evaluation. Thus, more accurate biomarkers are clearly warranted. Here, we investigated for the first time the predictive role of IDO‐1, a negative immune‐regulatory molecule, on clear cell RCC tissues of 15 patients undergoing nivolumab therapy. IDO‐1 and other immune inhibitory molecules (PD‐L1, PD‐L2, FOXP3) as well as ...
Source: Cancer Science - Category: Cancer & Oncology Authors: Tags: Original Article Source Type: research
AbstractThe prognosis of patients with metastatic renal cell carcinoma has drastically improved due to the development of molecular-targeted drugs and their use in clinical practice. However, these drugs cause some diverse adverse reactions in patients and sometimes affect clinical outcomes of cancer therapy. Therefore, predictive markers are necessary to avoid severe adverse reactions, to establish novel and effective prevention methods, and to improve treatment outcomes. Some genetic factors involved in these adverse reactions have been reported; however, perspectives on each adverse response have not been integrated yet...
Source: Medical Oncology - Category: Cancer & Oncology Source Type: research
Conclusion This early-stage study gives us some insights into factors that might influence people's responses to a specific type of cancer treatment (immunotherapy with monoclonal antibodies). The findings are of interest, but don't have any immediate implications for cancer treatment. We don't know what the conditions that required antibiotic treatment were and whether these could have affected the response to immunotherapy. We don't know whether the antibiotics themselves influenced how well the immunotherapy worked, or whether it was their effect on gut bacteria. We also don't know whether having high levels of part...
Source: NHS News Feed - Category: Consumer Health News Tags: Cancer Source Type: news
This study aimed to estimate important difference (ID) in FKSI DRS scores that is considered to be meaningful when comparing treatment effect between groups , using mRCC trial data.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Carcinoma | Food and Drug Administration (FDA) | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology